Lose the weight. Keep your edge.
Physician-prescribed Tirzepatide and Semaglutide — GLP-1 medications studied for chronic weight management. Treatment is not appropriate for everyone and is offered only when a licensed provider determines it is clinically appropriate.
Your options
Two medications. One mission.
Both work by mimicking gut hormones that regulate appetite, blood sugar, and metabolism. Your physician will recommend the best fit based on your goals and bloodwork.
Tirzepatide
Dual AgonistDual-action GLP-1 / GIP
A dual GLP-1 / GIP receptor agonist studied for chronic weight management. Individual results vary and depend on dose, adherence, diet, and exercise.
- Weekly subcutaneous injection
- Dual GLP-1 and GIP receptor agonist
- Compounded by licensed US pharmacies
- Titration-based dosing protocol
Retatrutide
InvestigationalTriple-action GLP-1 / GIP / Glucagon
An investigational triple-receptor agonist (GLP-1, GIP, glucagon). Not FDA-approved; available only as a compounded option at provider discretion where lawful.
- Weekly subcutaneous injection
- GLP-1, GIP, and glucagon receptor agonist
- Compounded by licensed US pharmacies
- Gradual titration protocol
Semaglutide
GLP-1GLP-1 receptor agonist
A GLP-1 receptor agonist studied for chronic weight management and appetite regulation. Individual results vary.
- Weekly subcutaneous injection
- GLP-1 receptor agonist
- Compounded by licensed US pharmacies
- Gradual dose escalation
Eligibility required. Treatment subject to physician approval based on your medical history and labs. Pricing starts at the listed amount and varies by medication, dose, and titration stage. Shipping is included; required labs are billed separately (see Order Labs).
Important safety information — GLP-1 medications
Boxed warning (Semaglutide, Tirzepatide): In rodent studies these medications caused thyroid C-cell tumors. It is unknown whether they cause medullary thyroid carcinoma (MTC) in humans. Do not use if you or a family member have a history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, fatigue, and injection-site reactions. Serious risks may include pancreatitis, gallbladder disease, kidney injury (from dehydration), severe hypoglycemia (especially with insulin or sulfonylureas), allergic reactions, diabetic retinopathy complications, and suicidal ideation.
Do not use during pregnancy or breastfeeding, if you have a history of pancreatitis, severe gastrointestinal disease (including gastroparesis), or known hypersensitivity to GLP-1 receptor agonists. Retatrutide is investigational and not FDA-approved for any indication.
Report side effects to your prescribing provider immediately. You may also report adverse events to the FDA at fda.gov/medwatch or 1-800-FDA-1088. For medical emergencies, call 911.
Why GLP-1
More than a number on the scale.
Suppress appetite
Feel full faster and stay satisfied longer.
Improve metabolic health
Better A1C, blood pressure, and cholesterol markers.
Sustainable results
Built for the long haul, not crash dieting.
Physician-monitored
Quarterly labs and unlimited messaging included.
Ready to lose the weight?
Take our 3-minute eligibility quiz. If you qualify, your medication ships within days.
Start the Quiz